Katerina Akassoglou, PhD
|School||UCSF School of Medicine|
|Address||1650 Owens St|
San Francisco CA 94107
|NINDS||2016||Research Program Award R35|
|Conrand N. Hilton Foundation||2015||Marilyn Hilton Award for Innovation in MS Research|
|ASPET||2015||Secretary/Treasurer Molecular Pharmacology |
|ASPET||2013||Molecular Pharmacology Executive Committee Member|
|F1000||2011||F1000 Neuronal and Glial Cell Biology Section member|
|NINDS||2010||EUREKA (Exceptional Unconventional Research Enabling Knowledge Acceleration)|
|The Vilcek Foundation ||2009||Vilcek Prize for Creative Promise Finalist Award|
|Dana Foundation||2007||Dana Award in Brain and Immunoimaging|
|ASPET & Eli Lilly||2007||The John J Abel Award in Pharmacology|
|The White House||2006||Presidential Early Career Award for Scientists and Engineers |
Areas of Investigation: Our lab studies mechanisms of neurovascular regulation of inflammation and tissue repair. Our current research focuses on identifying the molecular and cellular interface that blood proteins utilize to interact with nervous system cells and change their functions. Our ultimate goal is to target these interactions for therapeutic intervention in neurologic diseases.
Significance: Rupture of the vasculature allows the entry of blood proteins into the brain with subsequent edema formation and neuronal damage in a variety of neurologic diseases, such as stroke, multiple sclerosis (MS), Alzheimer's Disease (AD) and spinal cord injury. Our studies aim to unravel the molecular mechanisms of the CNS response to neurovascular changes with the ultimate goal to develop novel therapeutic strategies for neurologic diseases.
Approaches: We integrate animal modeling, histopathology, tissue culture and biochemistry techniques, as a multifaceted experimental approach to address the biological complexity of disease and repair mechanisms. We have developed in vivo imaging tools of the mouse brain and spinal cord that enable us to monitor disease processes in real time in the living animal.
Contributions: Our work showed that blood proteins are not merely markers of blood-brain barrier (BBB) disruption, but play a causative role in CNS disease by exerting both pro-inflammatory and neurodegenerative effects. Our studies identified fibrinogen as a potential novel target for therapeutic intervention in neuroinflammatory diseases and led to the design of inhibitory peptides that specifically inhibit the damaging proinflammatory effects of fibrinogen in the CNS without affecting its effects in blood coagulation. Our work also showed that removal of fibrin from the CNS via proteolytic degradation is regulated by the neurotrophin receptor p75NTR via a novel signaling pathway whereby p75NTR directly binds the phosphodieserase isoform PDE4A to compartmentalize cAMP signaling in cells. We also showed novel biological functions for p75NTR as a regulator of cell differentiation that is critical for the progression of fibrosis and tissue repair. Overall, our studies have suggested that bi-directional molecular mechanisms of communication between the blood and the brain determine the degree of damage and the regenerative potential of tissues within and outside of the nervous system.
Some questions addressed in ongoing studies
- What is the functional role of BBB disruption in inflammation and neurodegeneration in neurologic diseases?
- How does fibrinogen affect neuronal and glial functions?
- Can the beneficial effect of fibrinogen inhibition be exploited therapeutically?
- What are the biological functions of p75NTR?
Derived automatically from this person's publications.
People in Profiles who have published with this person.
People who share related concepts with this person.